Medline
MDLN

Medline (MDLN) analyst forecast and price target

Analyst forecast

Buy

Consensus of 29 analyst ratings

Buy
23
Hold
6
Sell
0
Average price target
$45.64+30.28% vs. last price
Last $35.03
Low $34.00High $55.00

Based on 11 analyst targets

Recent analyst ratings

FirmActionRatingPrice targetDate
BTIGMaintainedBuy$55.00Aug 27, 2026
JP MorganMaintainedOverweight$46.00 from $53.00Aug 12, 2026
Wells FargoMaintainedEqual-Weight$34.00 from $45.00Aug 11, 2026
Tigress FinancialMaintainedBuy$55.00 from $62.00Aug 11, 2026
TD CowenMaintainedBuy$45.00 from $53.00Aug 10, 2026
StifelMaintainedBuy$45.00 from $50.00Aug 6, 2026
Evercore ISI GroupMaintainedOutperform$39.00 from $48.00Aug 6, 2026
Truist SecuritiesMaintainedBuy$47.00 from $56.00Aug 6, 2026
RBC CapitalMaintainedOutperform$46.00 from $53.00Aug 6, 2026
BTIGMaintainedBuy$55.00Jul 31, 2026
BairdMaintainedOutperform$45.00 from $57.00Jun 3, 2026
BarclaysMaintainedOverweight$45.00 from $50.00Jun 1, 2026
BNP ParibasMaintainedNeutral$40.00 from $49.00May 14, 2026
Tigress FinancialMaintainedBuy$62.00 from $60.00May 13, 2026
BTIGMaintainedBuy$55.00May 7, 2026
BernsteinMaintainedOutperform$54.00 from $56.00May 7, 2026
CitigroupMaintainedBuy$55.00 from $60.00May 7, 2026
CitigroupMaintainedBuy$60.00Mar 11, 2026
JP MorganMaintainedOverweight$53.00 from $50.00Mar 10, 2026
BTIGMaintainedBuy$55.00Mar 9, 2026

Frequently asked questions

  • What is the price target for MDLN stock?

    The average 12-month analyst price target for Medline (MDLN) is $45.64, with a high estimate of $55.00 and a low of $34.00, across 11 analysts.

  • Is MDLN a buy, sell, or hold?

    Analysts covering Medline currently average a Buy rating: 23 buy, 6 hold and 0 sell, from 29 analysts. Ratings reflect analyst opinion, not investment advice.

  • What upside do analysts see for MDLN?

    The average price target of $45.64 implies 30.28% upside from the last price of $35.03.

  • What is the latest analyst rating on MDLN?

    On Aug 27, 2026, BTIG maintained Medline at Buy with a price target of $55.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.